Sulbactam is NOT appropriate as monotherapy for NDM-producing infections
Sulbactam alone has no activity against NDM-producing organisms because metallo-β-lactamases (including NDM) hydrolyze sulbactam, rendering it ineffective. The FDA-approved indications for ampicillin-sulbactam do not include carbapenem-resistant or metallo-β-lactamase-producing organisms 1.
Recommended Treatment Options for NDM Infections
For infections caused by NDM-producing organisms, ceftazidime-avibactam combined with aztreonam is the preferred regimen based on current guidelines 2. This combination showed:
- 30-day mortality of 19.2% vs 44% with other therapies (HR 0.37,95% CI 0.13-0.74)
- Lower clinical failure rates (HR 0.30,95% CI 0.14-0.65)
- Shorter hospital stays 2
The rationale: aztreonam is not hydrolyzed by metallo-β-lactamases, while ceftazidime-avibactam protects aztreonam from other β-lactamases that may be co-produced 3, 2.
Alternative option: Cefiderocol is recommended for metallo-β-lactamase-producing strains when aztreonam-avibactam is unavailable 4, 5.
Important Caveats About Sulbactam
Sulbactam-Durlobactam Exception
The newer combination sulbactam-durlobactam is FDA-approved for Acinetobacter baumannii infections 6, but:
- It has limited activity against NDM-producing Acinetobacter: six NDM-producing isolates showed elevated MICs, with one novel NDM-87 variant demonstrating higher resistance 7
- It is not indicated for NDM-producing Enterobacterales (like E. coli or Klebsiella)
- Not approved in Europe 4
High-Dose Ampicillin-Sulbactam
While high-dose ampicillin-sulbactam has been used for some carbapenem-resistant Acinetobacter infections 2, 8, this does not extend to NDM-producing organisms due to the mechanism of resistance.
Clinical Algorithm
- Confirm NDM production through molecular testing or phenotypic carbapenemase detection
- First-line: Ceftazidime-avibactam + aztreonam 2
- Alternative: Cefiderocol (especially if aztreonam-avibactam unavailable) 4, 5
- Avoid: Sulbactam monotherapy or ampicillin-sulbactam—these have no role in NDM infections
- Consider: Polymyxin-based combinations only as salvage therapy when preferred agents unavailable 2
The evidence quality for aztreonam-avibactam is very low but represents the best available data, and the mortality benefit is substantial enough to warrant strong consideration 2.